Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14088081 | 0.70 | HRH3 (0.41) | GPR119 | |
| SCHEMBL2629285 | 0.67 | KCNH2 (0.45) | KCNH2GPR119 | |
| SCHEMBL240638 | 0.65 | SMN1; SMN2 (0.47) | KCNH2GPR119 | |
| SCHEMBL10168488 | 0.65 | KCNH2 (0.33) | KCNH2GPR119 | |
| SCHEMBL82304 | 0.65 | — | — | |
| SCHEMBL81828 | 0.64 | HTR3A (0.52) | KCNH2GPR119 | |
| SCHEMBL8207362 | 0.64 | KCNH2 (0.43) | KCNH2GPR119 | |
| SCHEMBL2629281 | 0.63 | PLD1 (0.47) | KCNH2GPR119CHRNB2CHRNA4 | |
| SCHEMBL3837138 | 0.63 | ADRB1 (0.44) | — | |
| SCHEMBL807298 | 0.63 | ALDH1A1 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | BACE1, APP, BACE2 | KCNH2 2109/4885GPR119 709/4885CHRNB2 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.